An Analysis of Herpes Simplex Keratitis Treatment Market by Topical, Injection and Oral Route of Administration
An Increase in Research and Development Activities and Rise in Emerging Markets Provides Beneficial Opportunities for the Herpes Simplex Keratitis Treatment Market in the Forecast Period.
Herpes Simplex Keratitis Treatment Market Snapshot (2023 to 2033)
The anticipated size of the herpes simplex keratitis treatment market in 2022 was US$ 4,237.2 million and is estimated to be US$ 4,442.2 million in 2023. There are a few key factors that are anticipated to expand the herpes simplex virus treatment market such as:
Rise in the prevalence of herpes simplex virus infection.
Increase in the rate of new infections.
The advancement in the treatment and diagnostic methods.
Growing government funding.
Upsurge in the mode of transmission of the infectious disease.
According to the Future Market Insights analysis report, herpes simplex keratitis treatment market is projected to expand at a CAGR of 6.1% between 2023 and 2033, totaling around US$ 8,022.9 million by 2033.
The ongoing development of advanced healthcare infrastructures worldwide is likely to augment the demand for herpes simplex keratitis treatment in the assessment period. Herpes simplex virus keratitis is an infection of epithelial cells that are present on the surface of the eye. It also causes retrograde infection of nerves that serve the cornea.
Primary infection usually leads to the swelling of eyelids and the conjunctiva, as well as itchy, white lesions on the corneal surface. Some of the additional symptoms include sinusitis, mild to acute dryness, and dull pain in the eye.
Recurrent infection is often caused by the reactivation of the virus and transportation of the same from the nerve axon to sensory nerve endings. Antiviral treatment either in the form of topical medications or oral administration of famciclovir or valacyclovir for 10 to 14 days is required when keratitis occurs. The condition is diagnosed by a slit-lamp examination. The rising adoption of topical therapy owing to its high efficacy is anticipated to propel the market in the future years.
Attributes
Details
Projected Forecast Value (2022)
US$ 4,237.2 million
Projected Forecast Value (2023)
US$ 4,442.2 million
Projected Forecast Value (2033)
US$ 8,022.9 million
Growth rate
6.1% CAGR
Forecast period
2023 to 2033
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Herpes Simplex Keratitis Treatment Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)
Global herpes simplex keratitis treatment market expanded at a CAGR of 3.9% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 6.1% between 2023 and 2033.
Therapeutics segment includes valacyclovir drug considerably dominates the market as it is cost-effective, easily available, and effective in blocking the virus from reproducing in the body, thereby having advantages to controlling the symptoms of an outbreak.
Valacyclovir is most widely used for cold sores determinable to its high absorption rate. Efforts and investments are done for providing vaccination for the disease condition which is anticipated to boost the growth of the vaccine segment.
Increasing research and development activities conducted by numerous key players to launch new drugs are set to propel the market in the near future. The rising cases of herpes simplex virus type 2 and herpes simplex virus type 1 across the globe is another key factor that is estimated to bode well for the herpes simplex keratitis treatment market growth.
According to the World Health Organization (WHO), nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection across the globe, whereas around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. These numbers are set to surge in the upcoming years, thereby propelling the growth in this market.
Find your sweet spots for generating winning opportunities in this market.
Challenges Faced by the Herpes Simplex Keratitis Treatment Industry
Cost of Herpes Simplex Keratitis Treatment is High
The cost of herpes simplex keratitis treatment is high. As per a study conducted by a team of researchers at Saint Louis University, Missouri, people in the United States spend tens of millions for the treatment of this condition. Moreover, people, especially in emerging economies may not be able to spend a huge amount and this may hamper the herpes simplex keratitis treatment market growth in the future.
Region-wise Analysis
North America is Emerging as an Opportunistic Herpes Simplex Keratitis Treatment Market
North America is projected to remain at the forefront by procuring the notable herpes simplex keratitis treatment market share of 34.7% in the near future. Further, the increasing prevalence of infections associated with the herpes simplex virus in the United States is a leading factor that is likely to propel the market with a value share of 32%.
Sexually active individuals or those who have had 3 or more sex partners in their lifetime are at a high risk of developing type 1 keratitis.
According to the Centers for Disease Control and Prevention (CDC), 1 in 5 individuals have a Sexually Transmitted Infection (STI), such as genital herpes in the United States, totaling around 68 million infections. In addition to that, new STIs total around US$ 16 billion in direct medical costs. This trend is projected to continue throughout the evaluation period, thereby boosting North America’s market.
Asia Pacific is Contributing to the Growth of the Herpes Simplex Keratitis Treatment Market
The growing number of new product launches by reputed companies is expected to fuel the sales of herpes simplex keratitis treatment options in Asia Pacific. The surging number of clinical trials in China, India, and Australia is another significant factor that is estimated to augur well for the market. China is forecasted to expand at a CAGR of 7.8%, whereas India is forecasted to expand at 7.1% CAGR. Australia is forecasted to capture 8.4% CAGR. For example,
A hospital in Ghaziabad, India, reported the first-ever case of herpes simplex virus infection that was termed as ‘very dangerous.’ Doctors discovered that COVID-19-recovered patients who have weak immune systems are most likely to develop this condition. Thus, the rising incidence of life-threatening disorders across Asia Pacific is projected to accelerate the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Analysis
Acyclovir has a Dominant Share in the Market
Acyclovir has a significant position in the market with a value share of 29.8%. Acyclovir and its analogs, are considered to be the inhibitors of viral DNA replication and are the only approved medicines for HSV that are used for infection therapies.
Topical Route of Distribution Holds a Leading Position in the Market
Topical route of distribution holds a leading position in the market with a value share of 43.8%. Host tissue (cornea) may become effective for HSV infection and repetition with topical, intravitreal, or systemic medications. In humans, recurrent ocular HSV-1 disease has mainly contributed to the usage of prostaglandin agonists, corticosteroids, and inhibitors of angiogenesis.
Market Competition
The global herpes simplex keratitis treatment market contains a large number of big and small players. Some of them include Aurobindo Pharma, GlaxoSmithKline, Cipla, Blistex, Mylan, Vectans Pharma, Dr. Reddy's Laboratories, Bausch Health, Novartis International AG, and Jubilant Cadista among others.
The majority of the leading companies are increasingly focusing on mergers and acquisitions, as well as geographical expansions to gain a competitive edge in the market. Meanwhile, a few other key players are striving to come up with innovative products to fulfill the high unmet needs of patients across the globe.
In December 2022, Global private equity fund Blackstone’s planned to submit a non-binding bid to acquire the entire 33.47% promoter stake in Cipla, India’s third-largest generics company by revenues, which had sparked a debate over the company’s future.
In February 2023, Novartis, had mentioned that it is on track to become a pure-play innovative medicines company, uniquely positioned to leverage its global scale and R&D platforms. Its six multi-billion brands5 now represent 32% of our Innovative Medicines sales and are growing 26%.
Pluvicto and Scemblix had very strong launch performances, and the Leqvio launch continues to progress. Pivotal Ph3 readouts for two iptacopan studies and Pluvicto in earlier lines of therapy provide strong confidence for near to mid-term growth. Looking ahead, we have a catalyst rich pipeline with 15 pivotal readouts in the mid-term. We expect to continue to deliver improved financials and strengthen Novartis ESG foundations, on our journey to become most trusted and valued medicines company in the world”.
Scope of Report
Report Attributes
Details
Growth Rate
CAGR of 6.1% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug
Route of Administration
Region
Regions Covered
North America
Latin America
Western Europe
Eastern Europe
South Asia & Pacific
East Asia
The Middle East & Africa
Key Countries Profiled
The United States
Canada
Brazil
Mexico
Germany
The United Kingdom
France
Spain
Italy
Russia
Poland
Czech Republic
Romania
China
Japan
South Korea
India
Bangladesh
Australia
New Zealand
GCC countries
South Africa
Israel
Key Companies Profiled
GlaxoSmithKline
Vectans Pharma
Blistex
Bausch Health
Aurobindo Pharma
Dr. Reddy's Laboratories
Cipla
Jubilant Cadista
Mylan
Novartis International AG
Customization
Available Upon Request
Key Segments Profiled in the Herpes Simplex Keratitis Treatment Industry Survey
By Drug:
Famciclovir
Valacyclovir
Acyclovir
Other Drugs
By Route of Administration:
Topical
Injection
Oral
By Region:
North America
Latin America
Western Europe
Eastern Europe
South Asia & Pacific
East Asia
The Middle East & Africa
Frequently Asked Questions
What is the Recent Market Valuation?
The market is estimated to secure a valuation of US$ 4,442.2 million in 2023.
What is the Projected Size of the Market by 2033?
The global market size is expected to reach US$ 8,022.9 million by 2033.
What is the Growth Potential of the Market?
The growth potential of the market is 6.1% through 2033.
Which Factor is Helping the Market Advance?
Persistent research and development efforts are helping the market advance.
Which Factor is Derailing the Market Growth?
High cost of herpes simplex keratitis treatment is derailing the market growth.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
5.3.1. Famciclovir
5.3.2. Valacyclovir
5.3.3. Acyclovir
5.3.4. Other Drugs
5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Topical
6.3.2. Injection
6.3.3. Oral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Drug
8.2.3. By Route of Administration
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug
8.3.3. By Route of Administration
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug
9.2.3. By Route of Administration
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug
9.3.3. By Route of Administration
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Drug
10.2.3. By Route of Administration
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug
10.3.3. By Route of Administration
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Drug
11.2.3. By Route of Administration
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug
11.3.3. By Route of Administration
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Drug
12.2.3. By Route of Administration
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug
12.3.3. By Route of Administration
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug
13.2.3. By Route of Administration
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug
13.3.3. By Route of Administration
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug
14.2.3. By Route of Administration
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug
14.3.3. By Route of Administration
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug
15.1.2.2. By Route of Administration
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug
15.2.2.2. By Route of Administration
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug
15.3.2.2. By Route of Administration
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug
15.4.2.2. By Route of Administration
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug
15.5.2.2. By Route of Administration
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug
15.6.2.2. By Route of Administration
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug
15.7.2.2. By Route of Administration
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug
15.8.2.2. By Route of Administration
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug
15.9.2.2. By Route of Administration
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug
15.10.2.2. By Route of Administration
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug
15.11.2.2. By Route of Administration
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug
15.12.2.2. By Route of Administration
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug
15.13.2.2. By Route of Administration
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug
15.14.2.2. By Route of Administration
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug
15.15.2.2. By Route of Administration
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug
15.16.2.2. By Route of Administration
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug
15.17.2.2. By Route of Administration
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug
15.18.2.2. By Route of Administration
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug
15.19.2.2. By Route of Administration
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug
15.20.2.2. By Route of Administration
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug
15.21.2.2. By Route of Administration
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Drug
15.22.2.2. By Route of Administration
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Drug
15.23.2.2. By Route of Administration
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug
16.3.3. By Route of Administration
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. GlaxoSmithKline
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Vectans Pharma
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Blistex
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Bausch Health
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Aurobindo Pharma
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Dr. Reddy's Laboratories
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Cipla
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Jubilant Cadista
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Mylan
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Novartis International AG
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Pfizer Inc.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Sanofi S.A.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Merck & Co., Inc.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Western Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 12: Western Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 15: Eastern Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: East Asia Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 13: Global Market Attractiveness by Drug, 2023 to 2033
Figure 14: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 28: North America Market Attractiveness by Drug, 2023 to 2033
Figure 29: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Drug, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Drug, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Western Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 47: Western Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 48: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Western Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 55: Western Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 58: Western Europe Market Attractiveness by Drug, 2023 to 2033
Figure 59: Western Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 60: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Eastern Europe Market Value (US$ Million) by Drug, 2023 to 2033
Figure 62: Eastern Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 73: Eastern Europe Market Attractiveness by Drug, 2023 to 2033
Figure 74: Eastern Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 75: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 76: South Asia and Pacific Market Value (US$ Million) by Drug, 2023 to 2033
Figure 77: South Asia and Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 88: South Asia and Pacific Market Attractiveness by Drug, 2023 to 2033
Figure 89: South Asia and Pacific Market Attractiveness by Route of Administration, 2023 to 2033
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 91: East Asia Market Value (US$ Million) by Drug, 2023 to 2033
Figure 92: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 93: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: East Asia Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 100: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 101: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 103: East Asia Market Attractiveness by Drug, 2023 to 2033
Figure 104: East Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 105: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 106: Middle East and Africa Market Value (US$ Million) by Drug, 2023 to 2033
Figure 107: Middle East and Africa Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Drug, 2018 to 2033
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 118: Middle East and Africa Market Attractiveness by Drug, 2023 to 2033
Figure 119: Middle East and Africa Market Attractiveness by Route of Administration, 2023 to 2033
Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
